Aethlon medical announces peer-reviewed publication of two case studies of critically ill covid-19 patients treated with the hemopurifier®

San diego, oct. 12, 2021 /prnewswire/ -- aethlon medical, inc. (nasdaq: aemd), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced the publication of a manuscript in the peer-reviewed journal frontiers in medicine describing two cases of critically ill covid-19 patients treated with the hemopurifier®, aethlon's therapeutic blood filtration system. the publication, titled "removal of covid-19 spike protein, whole virus, exosomes and exosomal micrornas by the hemopurifier® lectin-affinity cartridge in critically ill patients with covid-19 infection," is available here: https://www.frontiersin.org/articles/10.3389/fmed.2021.744141/full the publication documents two critically ill covid-19 patients receiving a combined total of nine, six-hour hemopurifier® treatment sessions.
AEMD Ratings Summary
AEMD Quant Ranking